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We describe two HIV-infected patients with tuberculosis-associated immune reconstruction inflammatory syndrome (TB-IRIS):
one with “paradoxical” IRIS and the other with “unmasking” IRIS. TB-IRIS in HIV-infected subjects is an exacerbation of
the symptoms, signs, or radiological manifestations of a pathogenic antigen, related to recovery of the immune system after
immunosuppression. We focused on the radiological characteristics of TB-IRIS and the briefly literature review on this syndrome.
1. Introduction
Tuberculosis- (TB-) associated immune reconstruction in-
flammatory syndrome (TB-IRIS) is emerging as an important
early complication of combination antiretroviral therapy
(CART) in patients with HIV infection all over the world.
In Europe, and United States studies the reported incidence
of TB-IRIS was from 11% to 45% [1–4]. The frequency of
TB-IRIS among Croatian patients in the study of Puljiz and
colleagues in 2006 was 40.7% [5].
IRIS is a condition that results from rapid restoration of
pathogen-specific immune responses to opportunistic infec-
tions, causing either the deterioration of a treated infection or
the new presentation of a previously subclinical infection [6,
7]. There is no diagnostic test for IRIS, and a confirmation of
the disease relies heavily upon case definitions incorporating
clinical and laboratory data [7]. Case definitions for IRIS
were published by French and collaborators in 2004 and by
Shelburne and colleagues in 2006 [8, 9]. A case definition
specific for TB-IRIS was also suggested by Colebunders et al.
in 2006 [10]. However, clinical management and research on
IRIS were hindered by the lack of consensus case definitions
and definitions that are specific to particular opportunistic
infections [7]. To address this issue, in resource-limited
settings, an international meeting of researches working in
this field was convened in Kampala, Uganda in November
2006, and the international network for the study of HIV-
associated IRIS (INSHI) was formed [7]. INSHI published
criteria for “paradoxical” TB-IRIS and “unmasking” TB-
IRIS diagnosis in 2008 aimed for use in settings in which
laboratory infrastructure is often limited [7].
The phenomenon of “paradoxical” reaction during the
treatment of TB in which existing disease may worsen or new
lesions appear has been recognized formany years, before the
association with HIV coinfection [11]. Most reported cases
have complicated the treatment of lymph node or cerebral
disease, with enlargement of nodes seen in approximately
30% in one large series [12, 13]. In the past few years an
increase in the frequency and severity of paradoxical reac-
tions in association with HIV coinfection has been reported
both in patients receiving CART and those not on CART [1].
A diagnosis of “paradoxical” IRIS required both a diag-
nosis of TB and an initial response to antituberculous therapy
(ATT) together with at least one of four major or two of
three minor clinical criteria and exclusion of alternative
explanations (Table 1) [7, 14].
The INSHI definition of CART-associated “unmasking”
TB requires three criteria: not receiving TB treatment at
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Table 1: Case definition for “paradoxical” tuberculosis-associated immune reconstruction inflammatory syndrome (TB-IRIS) for use in
resource-limited settings [7].
Three components to this case definition:
(1) Antecedent requirements (both of the following requirements must be met):
(1) Diagnosis of TB Made before starting of combination antiretroviral therapy (CART) and should fulfill WHOcriteria
(2) Initial response to TB treatment The patient’s condition should have stabilized or improved on appropriate TB treatmentbefore CART initiation
(2) Clinical criteria
The onset of TB-associated IRIS manifestations should be within 3 months of CART initiation, reinitiation, or regimen change because of
treatment failure
Of the following, at least one major criterion or two minor clinical criteria are required:
Major criteria
New or enlarging lymph nodes, cold abscesses, or other tissue involvement
New or worsening radiological features of TB
New or worsening central nervous system CNS TB
New or worsening serositis
Minor criteria
New or worsening constitutional symptoms such as fever, night sweats, or weight loss
New or worsening respiratory symptoms as cough, dyspnea, or stridor
New or worsening abdominal pain accompanied by peritonitis, hepatomegaly,
splenomegaly, or abdominal adenopathy
(3) Excluded alternative explanations for clinical deterioration
Failure of TB treatment because of TB drug resistance
Poor adherence to TB treatment
Another opportunistic infection or neoplasm
Drug toxicity or reaction
Table 2: Provisional case definition for “unmasking” tuberculosis-associated immune reconstruction inflammatory syndrome (TB-IRIS) in
resource-limited settings [7].
“Unmasking” TB-IRIS (provisional)
The following could suggest a diagnosis of “unmasking” TB-associated IRIS:
Patient is not receiving treatment for TB when CART is initiated and then presents with active TB within 3 months of starting CART
And one of the following criteria must be met:
(1) Heightened intensity of clinical manifestations, particularly if there is evidence of a marked inflammatory
component to the presentation. Examples include TB lymphadenitis or TB abscesses with prominent acute
inflammatory features, presentation with pulmonary TB that is complicated by respiratory failure due to ARDS,
and those who present with a marked systemic inflammatory distress syndrome related to TB
(2) Once established on TB treatment, a clinical course that is complicated by a paradoxical reaction
CART initiation; diagnosis of active TB after CART initi-
ation; fulfilling World Health Organization (WHO) diag-
nostic criteria for TB [7]. Additional criteria required for
“unmasking” TB-IRIS are presentation within three months
of CART initiation and either “heightened intensity of clinical
manifestations or development of a paradoxical reaction once
on TB treatment (Table 2) [7, 14, 15].
In this case report and overview of the literature, we
present the disease spectrum of “paradoxical” and “unmask-
ing” TB-IRIS in two patients with complete resolution of
disease.
2. Patients and Methods
Both patients receivedmedical care at theUniversityHospital
for Infectious Diseases (UHID) in Zagreb, Croatia, which
provides comprehensive care of all HIV-infected patients in
Croatia. Croatia has a low-levelHIV epidemic, and therewere
792 registered HIV/AIDS cases at the end of 2009, according
to the HIV/AIDS Register of the Croatian National Institute
of Public Health [16, 17]. The definition of TB-IRIS in our
patients required a case definition criterion for “paradoxical”
TB-IRIS that consists of three components as displayed in
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Table 1 or fulfilling criteria of “unmasking” TB-IRIS displayed
in Table 2 [7]. Informed consent was obtained from both
patients granting us the permission to publish the details of
their medical presentation and management.
3. Case Presentations
3.1. Case 1 Patient with “Paradoxical” TB-IRIS. A 53-year-
old Caucasian female was admitted to UHID in December
2006 with a three-week history of fever and cough. HIV-1
infection was diagnosed in 2004, and CART was prescribed
in April 2004. However, the patient stopped taking CART in
December 2005.
At admission, chest radiographs showed patchy medial
lobe infiltrate and massive right hilar adenopathy. Native
and postcontrast thoracic computed tomography (CT) scan
confirmed large right side mediastinal and pulmonary lymph
nodes. High resolution CT scan of the right lung showed
peripheral, poorly defined, small (2–4mm diameter) cen-
trilobular nodules and branching linear opacities of similar
caliber originating from a single stalk (the “tree-in-bud”
pattern) [18].No cavitieswere detected. Sputumcultures grew
Mycobacterium tuberculosis (M. tuberculosis) sensitive to all
ATT drugs.
Standard ATT (isoniazid, rifampin, pyrazinamide, and
ethambutol) was initiated in December 2006 and was given
for 8weeks. After that, isoniazid and rifampin were given
for the period of 12months. CART (stavudine, lamivudine,
and efavirenz) was given 15 days after initiation of ATT. In
February 2007, three months after initiation of ATT, two
“cold” abscesses of thoracic wall were noticed and confirmed
by ultrasound (US) and CT imaging. We performed initial
aspiration biopsy to establish the diagnosis and to exclude
malignancy [19]. Eventually, surgical incision and drainage
was done. Pulmonary infiltrates at that time were completely
resolved. In August 2007, the patient noted enlarged cervical
lymph nodes. On physical examination performed at that
time, we found enlarged lymph nodes in the left anterior
cervical chain and left supraclavicular region (Figure 1). The
involved areas were minimally tender with no warmth or
erythema. The largest lymph node was approximately 3 ×
4 cm, and the consistency of the lymph nodes varied from
firm to fluctuant. CT and US scans of the neck, performed
in August 2007, revealed large left side lymphadenopathy
along the anterior cervical chain and in the supraclavicular
region. Most of the lymph nodes were noted to be necrotic.
A US-guided fine needle aspiration of two largest, necrotic
cervical nodes was performed. About 70mL of necrotic,
purulent material was removed. Cytological examination
showed granulomatous inflammation with caseous necrosis.
Acid-fast bacilli (AFB) were seen, but cultures did not grow
M. tuberculosis. IRIS was treated with steroids (methylpred-
nisolone) for 10months from January to November 2007.
The CD4 cell count and viral load (HIV RNA copies/mL)
over time are presented in Figure 2.
The patient’s health condition slowly improved over the
next 12months, and inAugust 2008, the neck lymphadenopa-
thy and thoracic wall abscesses had resolved with only scar
tissue remaining at the site of previous surgical incision.
Figure 1: Enlarged cervical lymph nodes in a patient (Case no. 1)
with “paradoxical” tuberculosis- (TB-) associated immune recon-
struction inflammatory syndrome (TB-IRIS) (arrow).
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Figure 2:The CD4 cell count and viral load (HIV RNA copies/mL)
over time in a patient with “paradoxical” tuberculosis- (TB-)
associated immune reconstruction inflammatory syndrome (IRIS).
CART: combination antiretroviral therapy.
3.2. Case 2 Patient with “Unmasking” TB-IRIS. A 40-year-old
Caucasian male came to a routine followup at the HIV/AIDS
Outpatient Center at the University Hospital for Infectious
Diseases (UHID) in Zagreb in February 2008. On physical
examination, a painless mass in the left inguinal region was
noted. The skin overlying the region was not erythematous,
and the patient had no fever. He stated having intermittent
low-grade fever and a minor swelling in the left groin since
October 2007.
He was known to be HIV infected after a tonsillectomy
performed in May 2007. Pathohistological examination of
the tonsils revealed chronic granulomatous infection. At that
time, he had a reactive purified protein derivative (PPD)
test which was positive (measured 18 × 20mm). The chest
X-ray was normal. CART was commenced with abacavir,
lamivudine, and efavirenz in July 2007. No TB prophylaxis
was given.
In a car accident in August 2007, he had lumbar region
contusion, and eventually the lumbar spine CT scan was
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Figure 3: CT scans demonstrated permeative bone destruction of the lower end plate of the fourth lumbar vertebra and the upper end
plate of the fifth lumbar vertebra, consistent with spondylodiscitis in a patient with “unmasking” tuberculosis- (TB-) associated immune
reconstruction inflammatory syndrome (TB-IRIS) (arrows) (Case no. 2).
Figure 4: Axial, contrast-enhanced abdominal computed tomography (CT) scans showed huge abscess in a left psoas muscle (arrows) in a
patient with “unmasking” tuberculosis- (TB-) associated immune reconstruction inflammatory syndrome (TB-IRIS) (Case no. 2).
performed to exclude bone fractures.TheCT scan showed no
evidence of traumatic or other bone lesions of lumbar spine
vertebrae. The paravertebral spaces were normal.
After the above mentioned visit in February 2008, the
patient was admitted to UHID. Abdominal US revealed
hypoechoic mass in the left psoas muscle extending in
the left inguinal region above the inguinal ligament. Axial,
contrast-enhanced lumbar spine and abdominal CT scans
demonstrated permeative bone destruction of the lower end
plate of the fourth lumbar vertebra and the upper end plate
of the fifth lumbar vertebra, consistent with spondylodiscitis
and a huge left psoas abscess (about 35 × 10 × 8 cm) (Figures
3 and 4).
A lumbar puncture was performed and was unremark-
able. The chest radiograph was normal. The blood CD4 cell
count was 185/mm3, and the HIV plasma viral load was <50
copies permL.Wepresent the bloodCD4 cell count andHIV-
1 RNA response to CART over time in Figure 5.
US-guided aspiration of psoas abscess was performed,
which revealed purulent material. AFB staining was positive,
and subsequently M. tuberculosis was cultured. It was sen-
sitive to all major AT drugs. The patient was subsequently
referred to the Department of Surgery at the University
Traumatology Clinic, Zagreb, where surgical drainage via an
extra peritoneal approach was performed. The abscess was
completely drained, and 1400mL of pus was evacuated.
Treatment with rifampin, ethambutol, isoniazid and
pyrazinamide was initiated in February 2008 and was given
for 8weeks. After that isoniazid, and rifampin were given for
the period of 12months.
Over the next nine month,s the patient had several
further outpatient follow-up visits. A follow-up magnetic
resonance imaging (MRI) examination of the spine was
performed in September 2008. It showed high signal intensity
of L4 and L5 lumbar vertebral bodies in T1- and T2-weighted
images (WIs) as signs of healing, with loss of height from
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Figure 5: The blood CD4 cell count and HIV-1 RNA response to
CART over time in a patient with “unmasking” tuberculosis- (TB-)
associated immune reconstruction inflammatory syndrome (TB-
IRIS). CART: combination antiretroviral therapy.
Figure 6: A follow-up magnetic resonance imaging (MRI) exam-
ination of the spine performed in September 2008 showed high
signal intensity of L4 and L5 lumbar vertebral bodies in T2-weighted
images (WIs) as signs of healing, with loss of height from infective
destruction. There was no spinal canal stenosis.
infective destruction. There was no spinal canal stenosis
(Figure 6). During the visit in November 2008, all signs and
symptoms of TB resolved.
4. Discussion
The patient with “paradoxical” form of TB-IRIS fulfilled
the INSHI criteria: the diagnosis of TB was made before
reinitiation of CART and fulfilledWHO criteria for diagnosis
of smear-positive pulmonary TB and extra pulmonary TB
[7]. The onset of TB-IRIS manifestation was within 3months
of CART initiation. The pulmonary infiltrate resolved after
two months of ATT, but at the same time thoracic wall cold
abscesses appeared, followed by enlarged, necrotic lymph
nodes at the supraclavicular region and neck. We excluded
possible alternative explanations for clinical deterioration:
poor adherence to ATT because the patient was hospitalized
and carefully monitored, and the presence of another oppor-
tunistic infection or neoplasm was excluded by different
diagnostic methods. Drug resistance was excluded by testing
with culture techniques [20].
The patient with spondylodiscitis and psoas abscess also
fulfilled the INSHI [7] criteria for “unmasking” TB-IRIS.
However, there is some uncertainty about the precise time
point of the onset of TB symptoms in relation to CART
initiation. Our patient recalled the first symptoms of TB
infection about threemonths afterCART initiation.However,
CT scans of lumbar spine and abdomen were performed
on his follow-up visit seven months after CART initiation
and showed signs of spondylodiscitis and psoas abscess.
Because of a car accident, a CT scan of lumbar vertebrae
was performed one month after CART initiation. It was
unremarkable; no signs of bone destruction or trauma were
found. The destruction of lumbar spine vertebrae and psoas
abscess gradually developed in the course of seven months.
Themarked inflammation that resembled a formation of large
psoas abscess supports the diagnosis of IRIS.
At the time when the patient was found to be HIV
infected, the PPD test was positive. Latent TB infection
(LTBI) is defined by a positive M. tuberculosis-specific
immune response in the PPD or an interferon-gamma release
assays (IGRAs) in the absence of active TB. A positive PPD
test indicates an immunologicalmemory to previous or ongo-
ing contact with M. tuberculosis and may be found also in
patients who were BCG vaccinated or who had contact with
atypical mycobacteria [21]. Our patient was BCG vaccinated
and we did not decide to give TB preventive chemotherapy.
Analyzing our decision in retrospect, it is possible that we
might have prevented the development of active TB by
introducing preventive chemotherapy. However, preventive
chemotherapy has no effect on the overall mortality [22].The
development of drug resistance to M. tuberculosis is also a
concern when preventive therapy is given.
The majority of patients with “unmasking” IRIS had a
pulmonary form of TB [23]. Only a few cases of TB spondy-
lodiscitis without pulmonary findings have been reported
[15, 24]. The lumbar and lower thoracic regions are most
commonly affected in spinal TB [25]. A high index of clinical
suspicion and an accurate history of possible TB exposure
are essential for the diagnosis of skeletal TB in HIV-infected
patients. Spinal TB has no specific diagnostic characteristics
or features on radiological imaging andmanifests in 2 distinct
forms: spondylodiscitis (classic) and spondylitis without
disc involvement (atypical) [26]. Involvement of contiguous
vertebrae is common [26]. Paraspinal abscesses can develop
in more than 50% of spinal TB cases, and the identification
of psoas abscess needs a prompt evaluation of the spine as a
primary source of infection [26, 27]. Microscopy and culture
of infected material are recommended for the diagnosis of
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spinal TB [25]. Needle aspiration and biopsy, preferably CT-
guided, are advocated and considered both sensitive and
specific [28].
“Paradoxical” reactions generally occur within 1 to
3months of initiation of treatment [29]. Why “paradoxi-
cal” reactions to drug therapy should occur only in some
individuals is unclear. It is likely to be due to a complex
interplay of the host immune responses, tubercle bacilli
virulence, antigen load, the site of infection, and the effects
of chemotherapy [30]. The massive delivery of membrane
antigens after the initiation of ATT has been advocated as
the cause of “paradoxical” responses in immunoincompetent
patients [30]. Another possible mechanism is immunologic
restoration after antiretroviral therapy and recovery of spe-
cific responses to certain antigens [1].
Themost frequent risk factors for the development of IRIS
found in the majority of studies were starting CART close
to the treatment of opportunistic infection, a low CD4 cell
count, and a high viral load [31]. In low-income countries,
in districts where TB and CART services are not integrated
and delivered in different localities, delays in starting CART
were largely attributable to the prolonged time between TB
diagnosis in the TB clinic and patients access to the CART in
the HIV clinic [32, 33].
The treatment of suppurative lymphadenitis and cold
abscesses includes drainage of the purulent material. Sponta-
neous drainage may result in scar formation; hence, repeated
punctures or surgical drainage is preferred. We performed
US-guided puncture and evacuation of necrotic neck lymph
nodes in our patient. The TB abscess of the chest wall was at
one time point incised and drained.
According to our experience and the literature search,
we recommend the following general principles of treatment
based on existing reports, trials, and expert opinions [14, 34–
39].
(i) Clinicians should become familiar with the case
definitions for TB-IRIS and use specific definitions
developed for resource-limited settings. Clinicians
should consider alternative diagnoses in patients with
suspected TB-IRIS, especially if the severity of the
condition warrants administering corticosteroids.
(ii) Patients should continue antituberculous therapy
without change unless there is a reason to suspect that
the current regimen is inadequate.
(iii) In nearly all cases, patient with TB-IRIS should
remain on antiretroviral therapy. Certain circum-
stances, however, may require temporary interrup-
tion of antiretroviral therapy, such as life-threatening
central nervous system complications of IRIS.
(iv) We recommend performing incision and drainage
(with stains and cultures) for localized abscesses, as
it was in the case of the psoas abscess in our patient.
(v) Although criteria for initiating corticosteroids remain
poorly defined, we recommend administering pred-
nisone for TB-IRIS cases when patients have persis-
tent fever that affects everyday activities.
(vi) The dosing and duration of corticosteroids should be
tailored to individual patient circumstances.
(vii) The patient receiving corticosteroids for TB-IRIS
should undergo careful monitoring for response to
corticosteroid therapy and monitoring for the devel-
opment of possible concurrent infections or other
corticosteroid side effects. Prophylaxis for oppor-
tunistic infections) should also be given.
(viii) If the patient’s clinical condition does not improve,
the clinician should consider an alternative diagnosis
and possible termination of corticosteroids, since
administering corticosteroids to a patient with a non
tuberculous opportunistic infection or disease could
result in further clinical deterioration.
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